Isolated cells from humanized FcγR mice
Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided.
1. A mouse lymphocyte comprising in its genome at least two low affinity human FcγR α-chain genes that replace the endogenous mouse low affinity FcγR α-chain genes, wherein the cell comprises a functional FcR γ-chain and functionally expresses the at least two low affinity human FcγR α-chain genes.
2. The lymphocyte of claim 1 , wherein the at least two low affinity human FcγR α-chain genes are selected from the group consisting of a human FcγRIIA α-chain gene, a human FcγRIIB α-chain gene, a human FcγRIIC α-chain gene, a human FcγRIIIA α-chain gene and a human FcγRIIIB α-chain gene.
3. The lymphocyte of claim 1 , wherein the at least two low affinity human FcγR genes are a human FcγRIIA α-chain gene and a human FcγRIIIA α-chain gene.
4. The lymphocyte of claim 3 , wherein the human FcγRIIIA α-chain comprises a phenylalanine at amino acid position 158.
5. The lymphocyte of claim 3 , wherein the human FcγRIIIA α-chain comprises a valine at amino acid position 158.
6. The lymphocyte of claim 1 , wherein the lymphocyte is a NK cell.
7. The lymphocyte of claim 1 , wherein the lymphocyte is a B cell.
8. The lymphocyte of claim 1 , wherein the lymphocyte is a B cell comprising a human nucleotide sequence that encodes a human CD20 protein, and wherein the lymphocyte does not express an endogenous mouse CD20 protein.
9. The lymphocyte of claim 1 , wherein the lymphocyte is an NK cell that expresses a human FcγRIIIA α-chain.
10. The lymphocyte of claim 1 , wherein the lymphocyte is an NK cell that expresses an α-chain of human FcγRIIC.
11. The lymphocyte of claim 1 , wherein the lymphocyte is a monocyte, a macrophage, a polymorphonuclear (PMN) cell, a basophil, an eosinophil, or a T cell, and wherein the lymphocyte expresses a human FcγRIIA α-chain.
12. The lymphocyte of claim 1 , wherein the genome of the lymphocyte comprises a human FcγRIIB α-chain gene, a human FcγRIIC α-chain gene, and a human FcγRIIIB α-chain gene.
13. The lymphocyte of claim 1 , wherein the functional FcR γ-chain is an endogenous FcR γ-chain.
14. A mouse NK cell comprising in its genome a human FcγRIIIA α-chain gene that replaces the endogenous mouse FcγRIIB, FcγRIII, and FcγRIV α-chain genes, wherein the NK cell functionally expresses the human FcγRIIIA α-chain gene on its surface with a mouse FcR γ-chain.
15. An isolated mouse lymphocyte whose genome comprises a human FcγRIIIA α-chain gene that replaces the endogenous mouse FcγRIIB, FcγRIII, and FcγRIV α-chain genes, wherein the lymphocyte functionally expresses a human FcγRIIIA α-chain on its surface with a mouse FcR γ-chain.